1/93
Looks like no tags are added yet.
-Initiate: Any time during illness
-Tx: Can be alongside life-prolonging therapy
-Diagnosis: Any serious illness
About Palliative Care
-Initiate: Prognosis of ≤6 months
-Tx: No further life-prolonging therapy (no chemo)
-Diagnosis: Terminal
About Hospice
-Loss of muscle mass
-Fatigue
-Anorexia
Anorexia/Cachexia Syndrome
-Olanzapine
-Megestrol Acetate (⚠️ INC'd risk for VTE)
-Corticosteroids (ehh, SEs w/ long-term use)
Appetite Stimulants for Cancer-Related Cachexia
Term used to describe ppts in whom death is imminent
Agonal
-Atropine q2hrs SQ PRN
-Glycopyrrolate (Robinul) q4hrs IVP/SQ PRN
Agents to help w/ Respiratory Secretions (end of life sx)
-Opioid rotation
-BZDs
Management of Myoclonus d/t opioids
Low dose Systemic Opioids (i.e. Morphine 1mg SQ/IV q2hrs PRN)
Agents to help manage Respiratory Dyspnea (end of life sx)
A written document indicating your wishes concerning medical tx if you are not able to give consent
Living Will
Names a person who will be authorized to make medical decisions on your behalf
Durable Power of Attorney (DPA) for Health Care
Orders healthcare professionals to NOT attempt cardiopulmonary resuscitation
Do Not Attempt Resuscitation (DNAR)
-Valid across the continuum of care
-Signed medical order
-Directs healthcare workers during medical emergencies (I want CPR vs I don't want CPR)
Portable Orders for Life-Sustaining Treatment (POLST)
-A third party performs the act that intentionally causes the ppt's death
-NOT legal in the USA
Euthanasia
-The ppt performs the act that intentionally causes his/her own death, although the means for causing death has been provided by a 3rd party (MD)
Physician-Assisted Aid in Dying
Patients:
-18+
-Residents of CA
-Mentally competent
-Estimated 6 month survival
-Must be able to self-administer med
Eligibility for EOLOA (california end of life option act)
-2 MDs must assess patient
-Ppt must make 2 verbal requests to MD at least 48H apart
-Ppt must make a witnessed written request for aid in dying drug
Legal Requirements for EOLOA
-Secobarbital
-Pentobarbital
→ Take on an empty stomach, take antiemetic 1 hour prior
Prescriptions for Aid in Dying
USP 800
Hazardous Drugs - Handling in Healthcare Settings
-Antineoplastic (cancer drug) NOT in final dosage form
-NON-antineoplastic HD (hazardous drugs) NOT in final dosage form
Store in Negative Pressure and Separate from non-HDs
NON-antineoplastic (non-cancer) Hazardous drugs (HD) IN FINAL Dosage Form
Clearly label and may Store w/ Non-HDs ✅
Vertical flow hoods ONLY:
-CACI (compounding aseptic containment isolator)
-BSC (class II biological safety cabinets)
C-PEC (primary engineering control)
-Room physically separated from non-HD compounding
-Negative pressure room (ISO 5)
-Externally vented
C-SEC (secondary engineering control)
We change these every 30 min
Double chemo gloves
We change these every 2-3 hours
Non-permeable gown
Put on your:
-Mask
-Beard cover
-Hair cover
-Shoe covers (2 pairs)
Donning: Outside the Anteroom
-Wash hands x30 seconds
-Put on 1st pair of gloves
-Put on non-permeable gown
-Alcohol your 1st gloves (should be under the gown cuff)
-Put on sterile (2nd pair) of gloves OVERR gown cuffs
-Alcohol your 2nd gloves
-Enter the C-SEC
Donning: After You Step into the Anteroom
-Remove outer glove (1 pair remaining)
-Remove gown
-Remove outer shoe cover (1 pair remaining)
-Dispose of all inside the C-SEC
Doffing: Inside C-SEC
-Remove hair cover
-Remove inner shoe cover
-Remove gloves
-Wash hands
Doffing: After Stepping out from C-SEC into the Anteroom
-No needles
-Prevent aerosolization
-Examples: Phaseal, Equashield
Closed System Transfer Devices (CSTD)
-DO NOT place liquid HDs in transport bags
-Do NOT tube liquid HDs or any Antineoplastic (onco drug)
-(usually we will spike the bags for the nurse to prevent spills/aerosolization)
Hazardous Drug Transport
-Needles
-Ampules
-Broken glass
-Razors
-Blades
-Sharps
→ Sharps Container (Red)
-Infectious waste
-Blood products (albumin, etc)
-Contaminated PPE
-IV tubing
-Cultures, stocks
→ Biohazard Container (Red)
-Empty vials
-Empty syringes, needles
-Empty IVs
-Gowns, gloves, aprons
-Tubing
-Wipes, packaging
→ Trace Chemo → Yellow Container
-Hazardous meds (RCRA)
-Half/partial doses (RCRA)
-P-listed drugs, packaging
-Bulk chemo
-Pathological waste **incineration only
→ Black Container
-Pills
-Injectables
-Antibiotics
→ Blue/White Container (pharm)
-Wash hands after handling
-Unused drug → DO NOT flush down toilet; give to med collection program
PATIENT Handling Oral Chemo Drug
-Avoid direct contact w/ meds!!! → Wear gloves
-Avoid if pregnant
-Partners to use effective birth control
CAREGIVER Handling Oral Chemo Drug
-Vinca alkaloids (vinblastine, vincristine, vinorelbine)
-Anthracyclines (doxorubicin, daunorubicin, epirubicin)
-Others (Dactinomycin, Mechlorthamine, Mitomycin)
Vesicant Chemo Agents
What is a vesicant?
Capable of causing tissue damage or necrosis
Central IV Lines (i.e. PICC line, Hickman, Groshong)
-IV infusions, IV push, IVPB OK
Safest route to Prevent Vesicant Extravasation
-No prolonged IV infusions
-IV push OR short infusions only
-AVOID hand/wrist areas; use "fresh" IV sites only
Peripheral IV Line: Prevent Vesicant Extravasation
Dexrazoxane IVPB
Antidote for Vesicant Extravasations d/t Anthracyclines
Hyaluronidase SQ
Antidote for Vesicant Extravasations d/t Vinca Alkaloids
Localize & Neutralize
-Stop infusion, leave IV cannula in place, Aspirate
-Apply COLD pack 🧊
-Use antidote: Dexrazoxane IVPB
Management of Vesicant Extravasation d/t Anthracyclines
Disperse and Dilute
-Stop infusion, leave IV cannula in place, Aspirate
-Apply WARM pack 🔥
-Use antidote: Hyaluronidase SQ
Management of Vesicant Extravasation d/t Vinca Alkaloids
-ONLY treats meningeal disease (CNS lymphoma, CNS leukemia)
-NOT indicated for Primary Brain Tumors
Intrathecal (IT) Chemotherapy
A small, dome-shaped plastic device surgically implanted under the Scalp and connected to a thin tube (catheter) placed inside a fluid-filled ventricle of the brain
Intrathcal Admin: Ommaya Reservoir
A needle inserted into the spinal column
Intrathecal Admin: Lumbar puncture
-Diluent must be in 0.9% NS
-All ingredients must be Preservative-free !!!
-Short expiration dating (
Intrathecal Preparation
MATH
-MTX
-Cytarabine (Ara-C)
-Thiotepa
-Hydrocortisone
Cancer Agents that can be given Intrathecally !!!
DO NOT give this med INTRATHECALLY → FATAL→ DEATH
Vinca Alkaloids
Bisphosphonates:
-Pamidronate (Aredia)
-Zoledronic Acid (Zometa)
RANKL Inhibitors:
-Denosumab (Xgeva)
Inhibitors of Osteoclast-mediated Bone Resorption
-****Nephrotoxicity (esp zoledronic acid); monitor SCr
**dose adj if CrCl
ADRs of IV Bisphosphonates
-Infuse ≥15 min for Zoledronic acid
-Infuse ≥2 hours for Pamidronate
**too rapid infusion rate → INC nephrotoxicity**
-Avoid giving if dehydrated
Admin of Bisphosphonates
-Atypical Femur Fractures**
-Infections**
-BBW ☠️ for HYPOcalcemia
-HYPOphosphatemia
-Osteonecrosis of Jaw
-Fetal harm**
-Fatigue, Asthenia
ADRs of Denosumab
-IVPB
-Q4 weeks
Admin of Bisphosphonates
-SQ
-Q4 weeks
Admin of Denosumab
-Osteolytic (direct bone destruction by tumor or metastasis)
-Humoral Circulating Factors (parathyroid hormone-related protein, PTHrP)
Pathophys of Hypercalcemia
If we get a DEC in PTH, we know the Hypercalcemia is...
Tumor-induced (TIH)
If we get an INC in PTH, we know the Hypercalcemia is...
Primary Hyperparathyroidism
(1)DEC'd neuromuscular excitability:
-CNS: Lethargy, Confusion, Delirium, Psychosis, Stupor
-Cardiac: Slowed conduction, Bundle branch block
-GI: NV, Constipation, Anorexia
(2)INC'd Diuresis, INC'd Sodium Retention
-Dehydration (DEC skin turgor, INC BUN:SCr ratio)
-Renal Insufficiency (INC in SCr, DEC in GFR)
**ppts are intravascularly volume depleted**
Sx of HYPERCalcemia
9 to 10.3
Normal Calcium Levels
[(normal albumin which is 4 - ppt's albumin) x 0.8] + ppt's calcium
Corrected Calcium Formula when Albumin is
Corrected Serum Calcium
Mild TIH
Corrected Serum Calcium 12-14 mg/dL
Moderate TIH
Corrected Serum Calcium >14 mg/dL
Severe TIH
-Thiazides
-Lithium
-Calcitriol
-Calcium
-Vit D
-NSAIDs
Meds that either INC Ca2+ or DEC GFR
**D/C these once we get TIH**
→ Encourage PO fluid intake
(IF NPO → NS IVF)
Management of Mild TIH w/ NO CNS Sx
→ NS IVF at 150-200 ml/hr
→ Bisphosphonate IVPB x1
+ (later) Furosemide once volume replenished!! To maintain UOP
Management of Moderate TIH w/ NO CNS Sx
→ NS IVF at 150-500 ml/hr
→ Bisphosphonate IVPB x1
→ Calcitonin SQ x48H
+ (later) Furosemide once volume replenished!! To maintain UOP
Management of Severe TIH OR Any TIH w/ CNS Sx
-Start at rate 150-500 ml/hr then adjust to maintain UOP of 100-150 ml/hr
-Use: 0.9% NS
-Caution in ppts unable to tolerate fluid loads
Intravenous Fluid Hydration in TIH
-Used to prevent symptomatic fluid overload
-MAY worsen renal insufficiency or intravascular volume depletion
-DO NOTTTT start until intravascular volume is replenished !!!
Furosemide in TIH
-Causes rapid lowering of serum Ca2+
-Reserved for severe TIH/CNS sx
-Limit duration to 48H d/t TACHYPHYLAXIS
-ADRs: Inj site rxn, flushing, nausea, hypersensitivity
Calcitonin (Miacalcin) in TIH
Important DOSINGGG TIBBIT for Bisphosphonates
No need to dose adj for SCr
-2nd line for Tx of Hypercalcemia
-Use if Refractory to Bisphosphonates OR if Bisphosphonates are contraindicated d/t severe renal impairment
-BBW: Severe (Fatal) HYPOcalcemia if CrCl
Denosumab in TIH
Patients w/ Cancer are _________
Hypercoagulable (clot more)
-Anticancer drugs (certain ones)
-Central venous catheters
-Surgeries
-Immobility
Risk Factors for VTE
-Tamoxifen
-CDK4/6 inhibitors
-Lenalidomide
-Bevacizumab
-ESAs
Cancer drugs that INC risk for VTE
Doppler Ultrasound
Diagnostic test for DVT
CT Pulmonary Angiogram
Diagnostic test for PE
→ UFH or LMWH
VTE Primary Ppx in ppts w/ Cancer: Hospitalized with Acute Illness or Reduced Mobility
→ UFH or LMWH for at least 7-10 days
VTE Primary Ppx in ppts w/ Cancer: Undergoing Major Surgery
→ ASA or LMWH
VTE Primary Ppx in ppts w/ Cancer: Myeloma and on Immunomodulatory-based Regimen [Lower Risk]
→ LMWH
VTE Primary Ppx in ppts w/ Cancer: Myeloma and on Immunomodulatory-based Regimen [Higher Risk]
(ONLY IF KHORANA SCORE ≥2)
→ Apixaban, Rivaroxaban, LMWH
VTE Primary Ppx in ppts w/ Cancer: Ambulatory Undergoing Chemo
-LMWH
-UFH**
-Fondaparinux**
-Rivaroxaban
-Apixaban
VTE Tx in ppts w/ Cancer [Initial Tx, ≥5-10 days]
-LMWH
-Rivaroxaban
-Apixaban
-Edoxaban**
(NO HEPARIN OR FONDA)
VTE Tx in ppts w/ Cancer [Long-term or Extended Tx, 6 or ≥6 months]
When do we do Extended VTE Tx (≥6 months)?
Persistent risk factors (like active cancer) present
→ AVOID DOACs (i.e. apixaban, rivaroxaban)
If Upper GI Malignancies
5000 units SQ q8-12H
Heparin Primary Ppx (VTE) Dose
18 units/kg/hr IV infusion
Heparin Initial Tx (VTE) Dose
This is NOTTT used in Long-term or Extended VTE Treatment
-Fondaparinux
-Heparin (UFH)
40 mg SQ q24H
Enoxaparin Primary Ppx (VTE) Dosing
-1 mg/kg SQ q12H
OR
-1.5 mg/kg SQ q24H
Enoxaparin Tx (initial and long-term/extended) Dosing for VTE